State MI
Clinical Trials in Michigan
Recruiting clinical trials with at least one study location in Michigan. Data updated daily from ClinicalTrials.gov.
Top Conditions in Michigan
NCT06524635 Phase 2
Recruiting
A Study to Assess Molecular Changes in Adult Participants With Moderate to Sever...
Condition
Hidradenitis Suppurativa
Enrollment
60 pts
Location
United States
Sponsor
AbbVie
NCT06072482 Phase 4
Recruiting
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
Condition
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Enrollment
300 pts
Location
United States, Czechia, Hungary
Sponsor
Amgen
NCT07094061 N/A
Recruiting
Neurobehavioral Signatures of Sign- and Goal-Tracking in Emerging Adults: Transl...
Condition
Substance Use
Enrollment
294 pts
Location
United States
Sponsor
University of Michigan
NCT05952024 Phase 2
Recruiting
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients ...
Condition
Diffuse Large B-Cell Lymphoma
Enrollment
80 pts
Location
United States, Brazil, Puerto Rico
Sponsor
AstraZeneca
NCT06752668 Phase 2
Recruiting
A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
Condition
Narcolepsy Type 1
Enrollment
96 pts
Location
United States, Canada
Sponsor
Centessa Pharmaceuticals (UK)
NCT06682988 Phase 2
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity in Participants ...
Condition
Advanced High-Grade Epithelial Ovarian
Enrollment
110 pts
Location
United States, Australia, Belgium
Sponsor
AbbVie
NCT03942653 Phase 2
Recruiting
Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen...
Condition
Salivary Gland Carcinoma
Enrollment
20 pts
Location
United States
Sponsor
Manish Patel
NCT06356571 Phase 2
Recruiting
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfil...
Condition
Plasma Cell Myeloma Refractory
Enrollment
64 pts
Location
United States
Sponsor
Sanofi
NCT04870944 Phase 1, Phase 2
Recruiting
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS ...
Condition
Diffuse Midline Glioma, H3 K27-Altered
Enrollment
63 pts
Location
United States, Australia
Sponsor
Children's Oncology Group
NCT06813911 Phase 3
Recruiting
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Partic...
Condition
Atherosclerotic Cardiovascular Disease (ASCVD)
Enrollment
340 pts
Location
United States, China, France
Sponsor
Novartis Pharmaceuticals
NCT05462704 Phase 3
Recruiting
Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy
Condition
Iron Deficiency Anemia
Enrollment
300 pts
Location
United States
Sponsor
Women and Infants Hospital of
NCT04064060 Phase 3
Recruiting
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Ot...
Condition
Myelodysplastic Syndromes (MDS)
Enrollment
665 pts
Location
United States, Australia, Belgium
Sponsor
Celgene
NCT05836324 Phase 1
Recruiting
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Met...
Condition
Solid Tumors
Enrollment
408 pts
Location
United States, Denmark, France
Sponsor
Incyte Corporation
NCT04097145 N/A
Recruiting
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
Condition
Tricuspid Regurgitation
Enrollment
870 pts
Location
United States, Canada
Sponsor
Edwards Lifesciences
NCT07301905 N/A
Recruiting
Culturally Targeted Health Communication and Receptivity to the Human Papillomav...
Condition
HPV Vaccination
Enrollment
265 pts
Location
United States
Sponsor
Michigan State University
NCT03016819 Phase 3
Recruiting
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarco...
Condition
Alveolar Soft Part Sarcoma
Enrollment
325 pts
Location
United States, China, Italy
Sponsor
Advenchen Laboratories, LLC
NCT07225946 Phase 3
Recruiting
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metas...
Condition
Prostatic Neoplasms, Castration-Resistant
Enrollment
800 pts
Location
United States, Australia, Brazil
Sponsor
Janssen Research & Development
NCT06972459 Phase 3
Recruiting
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight a...
Condition
Obesity
Enrollment
600 pts
Location
United States, Argentina, China
Sponsor
Eli Lilly and Company
NCT06292780 Phase 1, Phase 2
Recruiting
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or R...
Condition
Relapsed/Refractory Systemic Light Chain Amyloidosis
Enrollment
220 pts
Location
United States, South Korea, Spain
Sponsor
Regeneron Pharmaceuticals
NCT06118086 Phase 1, Phase 2
Recruiting
Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid...
Condition
Adenoid Cystic Carcinoma
Enrollment
100 pts
Location
United States, France
Sponsor
Remix Therapeutics
NCT05887973 N/A
Recruiting
Addressing Root Causes for Gun Violence Prevention (ARC-GVP)
Condition
Violence
Enrollment
250 pts
Location
United States
Sponsor
University of Michigan
NCT06925737 Phase 3
Recruiting
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Pros...
Condition
Prostate Cancer
Enrollment
1,440 pts
Location
United States, Argentina, Australia
Sponsor
Merck Sharp & Dohme LLC
NCT06841796 N/A
Recruiting
The YMCA Healthy Lifestyle Program for Prediabetes
Condition
PreDiabetes
Enrollment
84 pts
Location
United States
Sponsor
Young Men's Christian Associat
NCT05327686 Phase 2
Recruiting
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for t...
Condition
Metastatic Renal Cell Carcinoma
Enrollment
240 pts
Location
United States, Australia, Canada
Sponsor
NRG Oncology
NCT05803941 Phase 4
Recruiting
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With ...
Condition
Prostate Cancer
Enrollment
700 pts
Location
United States, Austria, Belgium
Sponsor
Novartis Pharmaceuticals